SecBot SecBot
PRESS-RELEASE ·Filed Aug 17, 2026

CHRS

Coherus Oncology, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Dividend
Actionable Insight • Neutral

The CVR dividend is a non-cash event with no immediate financial impact, but the sale process for biosimilar assets could unlock value. Monitor for updates on asset sales and any restrictions from the Loan Agreement. The CVRs expire in two years, so the timeline for monetization is uncertain.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

CHRS drug pipeline →

LOQTORZI

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially available in the U.S. since October 2023.
Next catalyst
None dated

What to watchLOQTORZI is a commercial-stage asset generating growing but still modest revenue (Q2 2026 net sales of $13.6M, up 15% sequentially). The company reported Q3 2026 results on November 9, 2026 with a $39.3M net loss and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer. Watch for Q3 LOQTORZI revenue trajectory and any updates on the expedited esophageal cancer development path. The stock trades near $0.84, down from a 52-week high of $2.62, reflecting the company's cash burn and pipeline-stage focus beyond LOQTORZI.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.34
T+0 close · Aug 17, 2026 · via day close
Latest settled
−52.17%
T+60 · $0.6409
Vs SPY
−50.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $1.34entry
  2. T+1 · 3mo ago −0.75%α −0.96% · $1.33
  3. T+5 · 3mo ago +2.24%α +2.44% · $1.37
  4. T+20 · 2mo ago −4.10%α −3.11% · $1.29
  5. T+60 · 6d ago −52.17%α −50.13% · $0.6409
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Coherus Oncology announced a special dividend of contingent value rights (CVRs) tied to the future sale of its remaining biosimilar assets, completing its transformation into a pure-play immuno-oncology company. The CVRs entitle holders to a pro rata share of net proceeds from the sale of patents, IP, royalties, and cell lines, but payments are uncertain and subject to a 2026 loan agreement. The CVRs expire on October 7, 2028, with no guaranteed payout, making this a speculative unlock of non-core asset value.

Key Facts

  • Coherus declared a special dividend of CVRs to stockholders of record as of September 30, 2026, with a distribution date of October 7, 2026.
  • CVRs entitle holders to net cash proceeds from the sale of Legacy BioSim Assets, including patents, IP, royalties, cell lines, and related materials.
  • The CVRs are non-transferable, will not be listed on any exchange, and expire on October 7, 2028, with no payment if no proceeds are received.
  • The company has retained an investment bank to assist in the sale process and is subject to restrictions under a Loan Agreement with Innovatus Life Sciences Lending Fund I, L.P., dated August 12, 2026.
  • Coherus is transforming into a fully integrated innovative oncology company focused on LOQTORZI (toripalimab-tpzi) and pipeline candidates casdozokitug and tagmokitug.

Financial Impact

No specific dollar amounts disclosed for the CVR proceeds; value depends on future sale of biosimilar assets, which are not quantified.

dilutioncash flow

Risk Factors

  • No guarantee of any payment under the CVRs if assets are not sold or monetized before expiration.
  • The Loan Agreement with Innovatus Life Sciences may restrict or delay the sale of Legacy BioSim Assets and CVR payments.
  • CVRs are non-transferable and have no public trading market, limiting liquidity for holders.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3346515

Track record

15 reports on CHRS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
  2. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
  3. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
  4. Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
  5. Aug 17, 202613w ago Press Release Neutral 4/10 Viewing Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
  6. Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
  7. Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
  9. May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
  10. May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026